HOME › DRUGS › SUMATRIPTAN
ACTIVE SUBSTANCE / INN

SUMATRIPTAN

Brand name(s): SUMATRIPTAN, IMITREX, Sumatriptan Galpharm, SUMATRIPTAN; NAPROXEN SODIUM, TOSYMRA
FDA LISTED
EMA LISTED
PRESCRIPTION
DISCONTINUED
REFUSED
Migraine Disorders
ANDA214209
ACTIVE SUBSTANCE
Sumatriptan
REGULATORS
FDA · EMA
SPONSORS / MAH
CIPLA, DR REDDYS LABS LTD, GLAXOSMITHKLINE
TOTAL APPLICATIONS
6
FDA APPLICATIONS (DRUGS@FDA)
BRAND NAMEAPPLICATIONSPONSORSTATUS
TOSYMRANDA210884TONIX MEDSPrescription
SUMATRIPTANANDA214209CIPLAPrescription
SUMATRIPTAN; NAPROXEN SODIUMANDA090930DR REDDYS LABS LTDNone (Tentative Approval)
IMITREXNDA020626GLAXOSMITHKLINEDiscontinued
IMITREXNDA020626GLAXOSMITHKLINEPrescription
EMA AUTHORISATIONS
PRODUCT NAMEHOLDERSTATUSDATEINDICATION
Sumatriptan GalpharmGalpharm Healthcare Ltd.RefusedMigraine Disorders

FULL INTELLIGENCE ON SUMATRIPTAN

Patent cliffs, clinical trials, pipeline data, AI-enriched regulatory signals — free on PharmaSignal.

OPEN PLATFORM →